The debate is over: accelerator MS provides the route to better drug-development paradigms/protocols

“Accelerator MS may be fulfilling its promise to make a real impact ... accelerator MS practioners are finding exciting applications and it is now up to industry to take the initiative.” Some time ago, Esther Schmid and I conducted a number of analyses relating to the introduction of technology, innovation and its impact on the productivity of drug R&D. Notwithstanding the fact that the new technology changed somewhat during the period, our conclusion was that 12–15 years was required before hard evidence of a positive change was seen. One example is high-throughput screening (HTS). The productivity of the technology was...